Vivodyne raised $40 million in Series A funding led by Khosla Ventures to enhance its AI-driven human predictive insights and open a new facility in San Francisco.

Vivodyne has raised $40 million in Series A financing to scale its robotics and AI approach for testing on lab-grown human tissues. The new funding will help open a 23,000-square-foot facility in South San Francisco, significantly increasing preclinical human testing capacity. This initiative aims to replace animal testing, which often leads to a 95% failure rate in clinical trials. The investment was led by Khosla Ventures, with participation from several other investors.